摘要
目的观察吉西他滨联合卡铂在晚期非小细胞肺癌（NSCLC）中的疗效和毒性。方法2006年1月至2008年6月共40例患者入组，中位年龄62岁（45—74岁）。治疗方案：第1、8天吉西他滨1000mg／m^2，卡铂350mg／m^2第3天，3周重复。结果40例患者共完成化疗102个周期，获PR16例，SD15例，PD9例。疾病进展时问和1年生存率分别为5．2个月和37．5％。主要毒副作用为骨髓抑制，包括白细胞减少、血小板降低和贫血。无治疗相关死亡。结论该剂量吉西他滨联合卡铂治疗方案在晚期NSCLC中疗效较好，毒副作用可耐受，值得临床进一步推广。
Objective To observe the gemcitabine combined with carboplatin in advanced non-small cell lung cancer （NSCLC） in the efficacy and toxicity. Methods From January 2006 to June 2008,40 patients were included , with a median age of 62-year-old （45-74）. Treatment gemcitabine 1000 mg/m^2, d1, d8, carboplatin 350 mg/m^2,d3, repeat for three weeks. Results 40 patients completed a total of 102 cycles of chemotherapy. PR16 cases were, SD15 cases, PD9） cases. Time to disease progression and 1-year survival rates were 5.2 months and 37.5%. The main toxicity was myelosuppression, included neutropenia thrombocytopenia and anemia. No treatment-related death. Conclusion The dose of gemcitabine combined with carboplatin in the treatment of advanced NSCLC in better efficacy, toxicity can be tolerated, it is worth to further promote clinical.
出处
《中国实用医药》
2009年第25期49-50,共2页
China Practical Medicine
关键词
非小细胞肺癌
化学疗法
吉西他滨
卡铂
Non-small cell lung cancer（NSCLC）
Chemotherapy
Gemeitabine
Carboplatin
